The genetic influences on oxycodone response characteristics in human experimental pain
- 3 June 2015
- journal article
- research article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 29 (4) , 417-425
Abstract
Human experimental pain studies are of value to study basic pain mechanisms under controlled conditions. The aim of this study was to investigate whether genetic variation across selected mu‐, kappa‐ and delta‐opioid receptor genes (OPRM1, OPRK1and OPRD1, respectively) influenced analgesic response to oxycodone in healthy volunteers. Experimental multimodal, multitissue pain data from previously published studies carried out in Caucasian volunteers were used. Data on thermal skin pain tolerance threshold (PTT) (n = 37), muscle pressure PTT (n = 31), mechanical visceral PTT (n = 43) and thermal visceral PTT (n = 41) were included. Genetic associations with pain outcomes were explored. Nineteen opioid receptor genetic polymorphisms were included in this study. Variability in oxycodone response to skin heat was associated with OPRM1 single‐nucleotide polymorphisms (SNPs) rs589046 (P < 0.0001) and rs563649 (P < 0.0001). Variability in oxycodone response to visceral pressure was associated with four OPRM1 SNPs: rs589046 (P = 0.015), rs1799971 (P = 0.045), rs9479757 (P = 0.009) and rs533586 (P = 0.046). OPRM1 SNPs were not associated with oxycodone visceral heat threshold, however, one OPRD1 rs419335 reached significance (P = 0.015). Another OPRD1 SNP rs2234918 (P = 0.041) was associated with muscle pressure. There were no associations with OPRK1 SNPs and oxycodone response for any of the pain modalities. Associations were found between analgesic effects of oxycodone and OPRM1 and OPRD1 SNPs; therefore, variation in opioid receptor genes may partly explain responder characteristics to oxycodone.Keywords
Funding Information
- Innovation Fund Denmark
- the Asmarley Trust and the Royal Marsden Palliative Care Research Fund
This publication has 45 references indexed in Scilit:
- Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical researchBritish Journal of Pharmacology, 2013
- Gender, Variation in Opioid Receptor Genes and Sensitivity to Experimental PainMolecular Pain, 2013
- Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic DrugsPharmacological Reviews, 2012
- Sensitivity to μ‐opioid receptor‐mediated anti‐nociception is determined by cross‐regulation between μ‐ and δ‐opioid receptors at supraspinal levelBritish Journal of Pharmacology, 2012
- Effect Sizes in Experimental Pain Produced by Gender, Genetic Variants and Sensitization ProceduresPLOS ONE, 2011
- Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational studyBritish Journal of Clinical Pharmacology, 2010
- Functional characterization of human variants of the mu-opioid receptor geneProceedings of the National Academy of Sciences, 2009
- Increased Sensitivity to Thermal Pain Following a Single Opiate Dose Is Influenced by the COMT val158met PolymorphismPLOS ONE, 2009
- Genetic Variation in the Serotonin Transporter Gene (5-HTTLPR, Rs25531) Influences the Analgesic Response to the Short Acting Opioid Remifentanil in HumansMolecular Pain, 2009
- Expansion of the human μ-opioid receptor gene architecture: novel functional variantsHuman Molecular Genetics, 2008